Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is
effective in slowing the rise of PSA as measured by PSA doubling time in men following
initial therapy for prostate cancer. Further, the investigators believe that POMx will be
shown to be safe and well tolerated.